NEW YORK, Jan. 17, 2018 /PRNewswire/ -- As you set your calendar for 2018, we at ExL Events want to make sure you and yourcolleagues are aware of two unique learning opportunities that we have planned. These programs are sure to deliver the innovative process improvements your organization is looking to achieve in 2018.
The Central Monitoring Summit, convening on March 22–23, 2018
Conference Co-Chairs:Lisa Berdan, PA, MHS, Executive Director, Global Megatrials, DUKE CLINICAL RESEARCH INSTITUTEKimberly Nessel, Director, Clinical Scientist CVM, THE JANSSEN PHARMACEUTICAL COMPANIES OF JOHNSON & JOHNSON
To see the full agenda, click here: https://goo.gl/W5XbT4 To register and save 15%, click here: https://goo.gl/WRRdTX
The Pharmacovigilance Audit and Inspections Conference, taking place on March 26–27, 2018 in Philadelphia, PA, will address how leaders in the life science industry are creating risk management plans, and utilizing the latest innovative tools and technologies to effectively prepare and improve their PV audit and inspection processes. Our expert speaking faculty will provide tactics to ensure proper pharmacovigilance processes, procedures and requirements to enhance your organization's safety performance and reporting.
Conference Chairperson:Susan Welsh, Chief Safety Officer, CSL BEHRING
To see the full agenda, click here: https://goo.gl/Cs5yPC To register and save 15%, click here: https://goo.gl/TyhdgB
Don't miss out on being part of a unique learning and networking opportunity. Register for these events and be sure to mention Discount Code EXLPR to receive 15% off standard registration rates.
For More Information, Contact: ExL Events Phone: +1 212-400-6240 Email: email@example.com
View original content:http://www.prnewswire.com/news-releases/dont-miss-out-on-developing-risk-management-system-improvements-300583257.html
SOURCE ExL Events
Subscribe to our Free Newsletters!
Collagen plays a crucial role in glowing skin, strong nails and shiny hair. You can boost collagen ...
CRISPR technology is a simple but potent tool for editing any part of the genome (complete set of ...
FDA recently approved Mogamulizumab-kpkc, a human monoclonal antibody prescribed for adult ...View All